Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neural Regulation01:37

Neural Regulation

43.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.9K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuroimaging runs on helium, helium runs through Hormuz.

Nature neuroscience·2026
Same author

Abdominal adiposity and Alzheimer's disease imaging markers across sex and race at midlife.

Journal of Alzheimer's disease : JAD·2026
Same author

DTI-ALPS index and its association with neuroinflammatory and neurodegenerative biomarkers and tau-PET in Alzheimer's continuum.

Neuroscience·2026
Same author

DTI-ALPS Is Associated with Temporolimbic Amyloid but Not Plasma p-Tau181 Across the Alzheimer's Disease Continuum.

Research square·2026
Same author

Longitudinal Degeneration of Microstructural and Structural Connectivity Patterns Following Stroke.

Stroke·2026
Same author

Vision Transformer-Based Segmentation of Abdominal Subcutaneous and Visceral Fat on MRI.

Journal of imaging informatics in medicine·2026

Related Experiment Video

Updated: Mar 7, 2026

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

18.2K

Does apolipoprotein A1 predict microstructural changes in subgenual cingulum in early Parkinson?

Farzaneh Rahmani1,2, Mohammad Hadi Aarabi3

  • 1NeuroImaging Network (NIN), Universal Scientific Education and Research Network (USERN), Tehran, Iran.

Journal of Neurology
|February 8, 2017
PubMed
Summary
This summary is machine-generated.

Higher Apolipoprotein A-1 (ApoA-1) levels correlate with specific white matter changes in Parkinson's disease (PD) patients. This blood marker may predict microstructural alterations in brain connectivity, offering new insights into PD progression.

Keywords:
Apolipoprotein A1ConnectometryDiffusion MRIEarly Parkinson’s diseaseSubgenual cingulum

More Related Videos

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

11.4K
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K

Related Experiment Videos

Last Updated: Mar 7, 2026

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

18.2K
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

11.4K
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K

Area of Science:

  • Neuroimaging
  • Biomarkers
  • Neurodegenerative Diseases

Background:

  • Higher plasma cholesterol is linked to reduced Parkinson's disease (PD) risk.
  • Apolipoprotein A-1 (ApoA-1), a marker of HDL-like particles, is associated with PD onset.
  • The relationship between serum ApoA-1 and structural brain connectivity in PD remains unclear.

Purpose of the Study:

  • To investigate the association between Apolipoprotein A-1 (ApoA-1) levels and structural brain connectivity in Parkinson's disease (PD) patients.
  • To utilize Diffusion Magnetic Resonance Imaging (MRI) Connectometry for exploring these associations.
  • To determine if ApoA-1 can serve as a predictive blood marker for microstructural brain changes in PD.

Main Methods:

  • Employed Diffusion Magnetic Resonance Imaging (MRI) Connectometry on 36 patients from the Parkinson's Progression Markers Initiative (PPMI).
  • Performed multiple regression analysis correlating diffusion MRI data with plasma ApoA-1 levels.
  • Reconstructed fiber pathways and extracted diffusion parameters, regressing them against ApoA-1 levels while controlling for age and sex.

Main Results:

  • Connectometry identified an association between ApoA-1 levels and the subgenual cingulum, a white matter tract.
  • Significant negative correlations were found between ApoA-1 and Quantitative Anisotropic (QA) in the left subgenual cingulum (r=-0.398, p=0.020).
  • ApoA-1 also showed a significant negative correlation with Generalized Fractional Anisotropic (GFA) in the right subgenual cingulum (r=-0.457, p=0.007).

Conclusions:

  • Apolipoprotein A-1 (ApoA-1) is associated with microstructural integrity of the subgenual cingulum in PD patients.
  • These findings suggest ApoA-1 as a potential blood-based biomarker for predicting white matter changes in PD.
  • This research provides novel insights into the link between a blood marker and brain connectivity in early-stage PD.